obesity

Aug 21, 2024

Obesity is the second leading cause of preventable death and is linked to numerous inflammatory conditions, which contribute to diseases like cardiovascular disease, diabetes, respiratory issues, mental health disorders, hypertension, obstructive sleep apnea, cancer, and high cholesterol. This poses a significant p...

Aug 09, 2024

More than 80 obesity drugs are currently in the pipeline with a strong emphasis on GLP-1 receptor agonists. Glucagon-like peptide-1 (GLP-1) receptor agonists are medications designed to treat type 2 diabetes mellitus and obesity by reducing blood glucose levels and regulating metabolism. Ongoing efforts by several ...

Aug 02, 2024

With the growing global health concern regarding obesity, Novo’s WEGOVY (semaglutide) has emerged as a leading solution in the weight loss treatment market. WEGOVY is a GLP-1 receptor agonist used alongside a low-calorie diet and increased physical activity. This obesity medication is administered as a weekly subcu...

Jul 24, 2024

Obesity is the second leading cause of preventable death, associated with a range of inflammatory conditions that contribute to cardiovascular disease, diabetes, respiratory problems, mental health issues, hypertension, obstructive sleep apnea, cancer, and high cholesterol. This represents a significant public heal...

Jul 03, 2024

Energy drinks have become a ubiquitous part of modern life, promising quick boosts of energy, enhanced mental alertness, and improved physical performance. These beverages are particularly popular among young adults, athletes, and professionals who often face demanding schedules and high levels of stress. However, ...

Jun 28, 2024

Obesity ranks as the second leading cause of preventable death, linked to the risk of inflammatory conditions that are directly and indirectly related to cardiovascular disease, diabetes, respiratory issues, psychological problems, hypertension, obstructive sleep apnea, cancer, and hyperlipidemia. This poses a majo...

Mar 20, 2024

Over the years, the landscape of Digestive Health Products has undergone significant evolution driven by advancements in scientific understanding, changing consumer preferences, and emerging market trends. As per the latest study by DelveInsight, the global Digestive Health Products market was valued at USD 39,345....

Mar 12, 2024

BeiGene Receives FDA Accelerated Approval for BRUKINSA in Relapsed/Refractory Follicular Lymphoma BeiGene, Ltd., has declared that the FDA has provided accelerated approval for BRUKINSA® (zanubrutinib) to be used in treating adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), when used alo...

Jan 02, 2024

Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase III Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy Cytokinetics, Incorporated released favorable top-line findings from the SEQUOIA-HCM trial (Safety, Efficacy, and Quantitative Understanding of Obst...

Dec 25, 2023

Prediabetes is a significant health concern characterized by elevated blood sugar levels that fall between the normal range and the diagnostic threshold for type 2 diabetes. Often labeled as borderline diabetes, this metabolic condition is intricately linked to the global rise in obesity and poses an escalating wor...